BNTC Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
14.4M
+6.2%
13.6M
+1.5%
13.4M
+36.5%
9.8M
-0.3%
9.8M
R&D
7.9M
+25.2%
6.3M
+8.0%
5.8M
+73.1%
3.4M
+17.5%
2.9M
SG&A
6.5M
-10.2%
7.3M
-3.4%
7.5M
+17.3%
6.4M
-7.7%
7.0M
Operating Income
-14430000
-6.2%
-13582000
-1.5%
-13377000
-36.5%
-9803000
+0.3%
-9834000
EBITDA
-14413000
-6.2%
-13568000
-1.5%
-13363000
-36.5%
-9790000
+0.3%
-9820000
Net Income
-12809000
-7.3%
-11935000
-0.8%
-11837000
-32.0%
-8965000
-1.8%
-8805000
EPS (Basic)
$-0.26
-8.3%
$-0.24
+7.7%
$-0.26
-18.2%
$-0.22
-4.8%
$-0.21
EPS (Diluted)
$-0.26
-8.3%
$-0.24
+7.7%
$-0.26
-18.2%
$-0.22
-4.8%
$-0.21
Shares (Diluted)
49.4M
-0.1%
49.4M
+7.4%
46.0M
+10.7%
41.5M
+1.0%
41.1M
Benitec Biopharma (BNTC) โ€” Financials